Nevada Gov Brian Sandoval signed the nation’s strictest bill targeting drug costs into law on Thursday, according to ABC News. It will require pharmaceutical companies to annually disclose drug list prices, profits made, and discounts given to market middlemen on insulin. Additionally, drug manufacturers must also provide state officials with written explanations regarding any insulin price hikes that surpass the previous years’ inflation rates, or are higher than twice the inflation rate of the previous 2 years. Market experts argue that transparency alone will not lower patient costs, but supporters of the bill said that it will start conversations, at the very least.
Chronic Lyme disease is controversial because there is no evidence that the bacteria remains in the body, and unproven treatments are resulting in a growing number of individuals with severe infections. In a new study, the authors used data from 5 cases to illustrate the negative impact a chronic Lyme diagnosis can have on a patient. According to Live Science, the investigators found most individuals who received treatments for chronic Lyme did not likely have the disease. One case described a teenage girl with muscle and joint pain, backaches, headaches, and lethargy for years, which resulted in a chronic Lyme disease diagnosis. She received antibiotics both orally and intravenously for 5 months, but experienced no improvements. Although the antibiotics were stopped, the catheter was left in and the girl developed a bacterial infection that spread to her blood, causing septic shock. It took several weeks of hospitalization for her to recover. “Chronic Lyme disease is a misleading term that should be avoided,” the authors concluded, as reported by Live Science.